Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Outcomes of the VictoTM adjustable artificial urinary sphincter in the treatment of male incontinence

J. Krhut, L. Bartáková, A. Kondé, RP. Sýkora, T. Rychlý, R. Zachoval

. 2025 ; 135 (1) : 103-109. [pub] 20240826

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002936

OBJECTIVES: To report the clinical outcomes of the VictoTM (Promedon, Cordoba, Argentina) adjustable artificial urinary sphincter (AUS) implantation in a cohort of patients with severe urinary incontinence (UI) after prostate surgery. PATIENTS AND METHODS: This study enrolled patients with UI following prostate surgery who underwent a Victo implantation between May 2018 and December 2023. Patients were prospectively evaluated at baseline, and at 3 and 12 months after device activation, and thereafter annually. The 24-h pad-weight test (24hPWT) was used to assess severity of UI, while the Patient Global Impression of Improvement (PGI-I) and patient satisfaction according to a Likert scale were used to measure patient-reported outcomes. RESULTS: A total of 96 patients with a median (interquartile range [IQR]) age of 68 (65-72) years were included in the final analysis. The median (IQR) follow-up was 3 (1-4) years. In all, 10 patients completed the 5-year follow-up. After the treatment, we observed a significant reduction in 24hPWT by the median of 83% (P < 0.001) at 3 months and by a median of 79% (P < 0.001) at 3 years. According to the PGI-I, a total of 87%, 92%, 87%, 81%, 83%, and 50% (five of 10) of patients rated their condition/incontinence as 'very much improved', 'much improved' or 'little improved' at 3 months, 1-, 2-, 3-, 4-, and 5-year follow-up visits, respectively. The proportion of patients, who were 'very satisfied' or 'satisfied' with the treatment outcome was 79%, 80%, 75%, 69%, 80%, and 60% (six of 10) at 3 months, 1-, 2-, 3-, 4-, and 5-years, respectively. There were a total of 13 (14%) device failures during the follow-up period. CONCLUSION: In conclusion, our data suggest that Victo AUS significantly reduces the severity of UI after prostate surgery and provides a reasonably high patient-reported satisfaction with treatment outcomes at mid-term follow-up.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002936
003      
CZ-PrNML
005      
20250206103947.0
007      
ta
008      
250121s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bju.16511 $2 doi
035    __
$a (PubMed)39187277
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Krhut, Jan $u Department of Urology, University Hospital, Ostrava, Czech Republic $u Department of Surgical Studies, Ostrava University, Ostrava, Czech Republic $1 https://orcid.org/0000000342055926 $7 mzk2005309234
245    10
$a Outcomes of the VictoTM adjustable artificial urinary sphincter in the treatment of male incontinence / $c J. Krhut, L. Bartáková, A. Kondé, RP. Sýkora, T. Rychlý, R. Zachoval
520    9_
$a OBJECTIVES: To report the clinical outcomes of the VictoTM (Promedon, Cordoba, Argentina) adjustable artificial urinary sphincter (AUS) implantation in a cohort of patients with severe urinary incontinence (UI) after prostate surgery. PATIENTS AND METHODS: This study enrolled patients with UI following prostate surgery who underwent a Victo implantation between May 2018 and December 2023. Patients were prospectively evaluated at baseline, and at 3 and 12 months after device activation, and thereafter annually. The 24-h pad-weight test (24hPWT) was used to assess severity of UI, while the Patient Global Impression of Improvement (PGI-I) and patient satisfaction according to a Likert scale were used to measure patient-reported outcomes. RESULTS: A total of 96 patients with a median (interquartile range [IQR]) age of 68 (65-72) years were included in the final analysis. The median (IQR) follow-up was 3 (1-4) years. In all, 10 patients completed the 5-year follow-up. After the treatment, we observed a significant reduction in 24hPWT by the median of 83% (P < 0.001) at 3 months and by a median of 79% (P < 0.001) at 3 years. According to the PGI-I, a total of 87%, 92%, 87%, 81%, 83%, and 50% (five of 10) of patients rated their condition/incontinence as 'very much improved', 'much improved' or 'little improved' at 3 months, 1-, 2-, 3-, 4-, and 5-year follow-up visits, respectively. The proportion of patients, who were 'very satisfied' or 'satisfied' with the treatment outcome was 79%, 80%, 75%, 69%, 80%, and 60% (six of 10) at 3 months, 1-, 2-, 3-, 4-, and 5-years, respectively. There were a total of 13 (14%) device failures during the follow-up period. CONCLUSION: In conclusion, our data suggest that Victo AUS significantly reduces the severity of UI after prostate surgery and provides a reasonably high patient-reported satisfaction with treatment outcomes at mid-term follow-up.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a umělý močový svěrač $7 D016741
650    _2
$a senioři $7 D000368
650    12
$a inkontinence moči $x chirurgie $x terapie $7 D014549
650    _2
$a výsledek terapie $7 D016896
650    12
$a prostatektomie $x škodlivé účinky $7 D011468
650    _2
$a prospektivní studie $7 D011446
650    _2
$a spokojenost pacientů $7 D017060
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pooperační komplikace $7 D011183
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bartáková, Lucie $u Department of Urology, 3rd Faculty of Medicine of Charles University and Faculty Thomayer Hospital, Prague, Czech Republic $1 https://orcid.org/0009000434390032
700    1_
$a Kondé, Adéla $u Department of Applied Mathematics, Faculty of Electrical Engineering and Computer Science, VSB - Technical University, Ostrava, Czech Republic $u Department of the Deputy Director for Science, Research and Education, University Hospital, Ostrava, Czech Republic
700    1_
$a Sýkora, Radek Paus $u Department of Urology, University Hospital, Ostrava, Czech Republic $u Department of Surgical Studies, Ostrava University, Ostrava, Czech Republic
700    1_
$a Rychlý, Tomáš $u Department of Urology, University Hospital, Ostrava, Czech Republic $u Department of Surgical Studies, Ostrava University, Ostrava, Czech Republic $1 https://orcid.org/0000000219727870
700    1_
$a Zachoval, Roman $u Department of Urology, 3rd Faculty of Medicine of Charles University and Faculty Thomayer Hospital, Prague, Czech Republic
773    0_
$w MED00011371 $t BJU international $x 1464-410X $g Roč. 135, č. 1 (2025), s. 103-109
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39187277 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103943 $b ABA008
999    __
$a ok $b bmc $g 2262995 $s 1238943
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 135 $c 1 $d 103-109 $e 20240826 $i 1464-410X $m BJU international $n BJU Int $x MED00011371
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...